Safety of biologic disease modifiers in rheumatoid arthritis in a clinical setting as a function of their responsiveness and correlation with clinical outcomes biomarkers in RA.
This study examines the safety and efficacy of standard treatments for Rheumatoid Arthritis in a clinical setting rather than a trial setting. In other words, using the Rheumatology Health Tracking system, we are studying the effects therapies have the way that they are prescribed in the "real world".
PI: Jeffrey Lisse, MD
Agency: Centocor, Inc.